Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248092 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
A Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity, sponsored by New River Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00248092: Completed Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity, sponsored by New River Pharmaceuticals.
NCT00248092 is a Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity that has completed, run by New River Pharmaceuticals. The registered enrollment target is 36 participants, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00248092, a Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity, has completed, sponsored by New River Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational drug. This means that it has not been approved by the U.S. Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss.
Conditions Studied
Interventions
- DRUG NRP104
Study Locations (1)
Maryland
- Johns Hopkins Bayview Medical Center, Clinical Studies Program - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
What the finished NCT00248092 record still lists
NCT00248092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which NRP104 is the first listed.
NCT00248092 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00248092 about?
NCT00248092 is a clinical study titled "Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse". This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational...
What is the current status of trial NCT00248092?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2006-01. Estimated completion is 2006-05.
What conditions does trial NCT00248092 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders.
What interventions are being tested in trial NCT00248092?
The interventions under investigation include: NRP104 (DRUG).
Who is sponsoring clinical trial NCT00248092?
This trial is sponsored by New River Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248092 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00248092's enrollment target sits among peer trials
36 51st of 58 higher than 7 of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Clinical Trial of Computer-based Motivational Intervention - 1
COMPLETED · Phase 1
-
Cognitive Therapy for PTSD in Addiction Treatment
COMPLETED · Phase 1
-
Prepulse Inhibition of Startle in Cocaine Dependence - 7
COMPLETED · Phase 1
-
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
COMPLETED · Phase 1
-
Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia